Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
Release Date: October 29, 2018
Expiration Date: October 29, 2019
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
With many new and emerging drug classes for the treatment of relapsed/refractory multiple myeloma (RRMM), it can be challenging to determine the optimal approach to sequencing treatment for patients with the disease. This activity will compare efficacy and safety data on new and emerging therapies in RRMM and provide strategies for incorporating risk-adapted treatment decisions to optimize patient outcomes.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast new and emerging drug classes for the treatment of relapsed/refractory multiple myeloma
- Identify the efficacy and safety of new and emerging therapies for the treatment of multiple myeloma in the relapsed/refractory setting
- Incorporate risk-adapted treatment decisions for the management of patients with relapsed/refractory multiple myeloma
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient – Paul G. Richardson, MD
Instructions for Participation and Credit
This activity is eligible for credit through October 29, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute where he is a Professor of Medicine at the Harvard Medical School. In addition, Dr. Richardson serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma.
Dr. Richardson is board certified in hematology, internal medicine, and medical oncology. He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Clinical Cancer Research, Bone Marrow Transplantation, JAMA Oncology, and the British Journal of Haematology. Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-029-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Paul Richardson has received honoraria related to formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides, AB, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb Company, Celgene, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.